Vaping-Related Deaths: Verified Causes, Patterns, and Public-Health Context Through 2025

What Are Vaping-Related Deaths and Why Does the Topic Matter in 2025

Vaping-related deaths refer to fatalities in which e-cigarette or vaping product use is determined by health investigators to have played a contributory or primary role, often assessed through standardized public-health investigations. As of 2025, the most consistently documented cluster of vaping-associated fatalities is linked to e-cigarette, or vaping, product use-associated lung injury (EVALI), which emerged in 2019 and peaked in 2020 in the United States. Continued surveillance through 2025 shows that EVALI cases have declined sharply from peak levels but underscores enduring risks from illicit THC products and unregulated chemical exposures. Understanding these deaths matters because it clarifies real risks versus perceived harms, informs policy and cessation strategies, and helps individuals make evidence-based choices about nicotine and cannabis delivery.

EVALI as a Primary Cause: Definition, Mechanism, and Ongoing Relevance

EVALI is a severe lung injury associated with vaping products, characterized by respiratory symptoms, imaging evidence of pneumonia, and, in severe cases, respiratory failure or death. Public-health investigations established that vitamin E acetate (VEA) in illicit THC vaping products was a primary culprit in most U.S. EVALI deaths, with medium-chain triglyceride (MCT) oils and other additives also implicated. While EVALI cases fell dramatically after 2020 as regulators curttered illicit THC markets and manufacturers reformulated products, sporadic cases and deaths reported through 2025 highlight persistent dangers from unregulated markets and non-legal substances.

How EVALI Differs From Other Vaping-Related Harms

• EVALI is a distinct syndrome tied primarily to illicit THC products and contaminants, not to nicotine-only e-cigarettes in regulated markets.
• Unlike chronic lung disease, EVALI presents acutely with cough, shortness of breath, and chest pain, often progressing rapidly without prompt care.
• Confirmed EVALI deaths typically show lipid-laden macrophages and acute lung injury in pathology, supporting a toxic-inhalation injury mechanism.

Surveillance Data and Trends Leading Into 2025

Through 2025, national and state surveillance systems such as CDC’s EVALI dashboard and the FDA’s CAERS database continue to inform understanding of vaping-associated mortality. Key patterns include geographic clustering in states with high illicit THC markets, younger adult demographics, and polysubstance use preceding illness. Although case counts have returned to low baseline levels in many jurisdictions, under-reporting, diagnostic delays, and evolving product formulations mean that definitive long-term mortality trends remain uncertain.

Snapshot of Documented U.S. EVALI Deaths (Core Metrics)

Other Documented Causes of Vaping-Associated Death

Beyond EVALI, public-health agencies have identified deaths where vaping contributed through alternate pathways, including nicotine poisoning (often from refillable high-concentration liquid exposure), traumatic injuries from device explosions, and acute cardiovascular events in individuals with preexisting conditions. Context matters: many cases involve polysubstance use, making attribution complex. As of 2025, no single non-lung mechanism has matched EVALI in case fatality volume, but product risks like battery safety and chemical aerosol contents remain active evaluation areas.

Contributing Factors and Product Characteristics

• Illicit THC oils with vitamin E acetate and other unlisted additives.
• Nicotine concentration and accidental exposure via spills or refilling errors.
• Device malfunction or improper battery handling leading to burns or explosions.

Risk Factors, Patterns, and Who Has Been Most Affected

Demographic and behavioral patterns help clarify who faces elevated risk. EVALI and other vaping-associated deaths have disproportionately affected younger adults and individuals who vape THC, often obtained off-market or from informal sources. Underlying lung disease, smoking combustible cigarettes, and recent use of both nicotine and THC vaping products further increase vulnerability. Public-health messaging emphasizes that legal, regulated nicotine products (e.g., FDA-approved NRT or combustible cigarettes) carry very different risk profiles than illicit vaping products.

Key Risk Indicators Through 2025

• Use of THC vaping products obtained from informal or illicit markets.
• Additives or diluents not listed on labeled products, especially vitamin E acetate.
• History of smoking combustible cigarettes or concurrent dual use.
• Pre-existing respiratory or cardiovascular conditions.
• Younger age and delayed healthcare-seeking when symptoms appear.

Public-Health Responses and Ongoing Prevention Efforts

Since 2019, governments have implemented tighter product regulations, marketing restrictions, and surveillance systems to curb vaping-related harm. In the U.S., the FDA’s enforcement actions targeting unauthorized flavored vaping products, including many illicit THC cartridges, contributed to reduced EVALI incidence. By 2025, many public-health agencies continue to fund quitlines, promote FDA-authorized cessation aids, and support product standards that reduce contaminant risks. These efforts highlight the importance of regulation, product transparency, and access to cessation support as durable components of harm reduction.

What Works: Evidence-Based Protections and Behaviors

• Use only legal, regulated nicotine or cannabis products with verified ingredients.
• Avoid modifying devices or adding non-approved substances to e-liquids.
• Seek medical care promptly for persistent cough, shortness of breath, or chest pain after vaping.
• Leverage FDA-authorized cessation tools for quitting combustible or nicotine-dependent behaviors.
• Support policies that limit youth access, restrict illicit sales, and mandate product reporting.